Aptorum Group Limited - Class A Ordinary Shares (APM): Price and Financial Metrics
GET POWR RATINGS... FREE!
APM Stock Summary
- APM has a higher market value than only 4.32% of US stocks; more precisely, its current market capitalization is $10,582,446.
- Revenue growth over the past 12 months for APTORUM GROUP LTD comes in at 129.9%, a number that bests 94.58% of the US stocks we're tracking.
- The volatility of APTORUM GROUP LTD's share price is greater than that of 97.55% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to APTORUM GROUP LTD, a group of peers worth examining would be HCWB, TDUP, FBIO, ZLAB, and RYTM.
- APM's SEC filings can be seen here. And to visit APTORUM GROUP LTD's official web site, go to www.aptorumgroup.com.
APM Valuation Summary
- In comparison to the median Healthcare stock, APM's EV/EBIT ratio is 109.09% lower, now standing at -0.6.
- APM's price/earnings ratio has moved up 60.7 over the prior 52 months.
Below are key valuation metrics over time for APM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| APM | 2023-03-24 | 7.4 | 0.5 | -1.0 | -0.6 |
| APM | 2023-03-23 | 7.2 | 0.5 | -0.9 | -0.6 |
| APM | 2023-03-22 | 6.7 | 0.4 | -0.9 | -0.5 |
| APM | 2023-03-21 | 5.9 | 0.4 | -0.8 | -0.4 |
| APM | 2023-03-20 | 5.9 | 0.4 | -0.8 | -0.4 |
| APM | 2023-03-17 | 6.1 | 0.4 | -0.8 | -0.5 |
APM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- APM has a Quality Grade of C, ranking ahead of 44.63% of graded US stocks.
- APM's asset turnover comes in at 0.027 -- ranking 360th of 680 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows APM's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2020-12-31 | 0.027 | -0.114 | 0.220 |
| 2019-12-31 | 0.016 | -0.485 | -0.814 |
APM Price Target
For more insight on analysts targets of APM, see our APM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $15.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
APM Stock Price Chart Interactive Chart >
APM Price/Volume Stats
| Current price | $2.98 | 52-week high | $17.80 |
| Prev. close | $3.35 | 52-week low | $2.31 |
| Day low | $2.78 | Volume | 17,200 |
| Day high | $3.35 | Avg. volume | 11,481 |
| 50-day MA | $3.74 | Dividend yield | N/A |
| 200-day MA | $8.64 | Market Cap | 10.64M |
Aptorum Group Limited - Class A Ordinary Shares (APM) Company Bio
Aptorum Group Ltd. is a pharmaceutical company, which engages in the development and commercialization of therapeutic and diagnostic technologies. It operates through the Therapeutics and Non-Therapeutics segments. The Therapeutics segment seeks to develop various drug molecules and certain technologies for the treatment and diagnosis of human disease conditions in neurology, infectious diseases, gastroenterology, oncology, and other disease areas. The Non-Therapeutics segment encompasses the development of surgical robotics and medical devices; and the activities of AML Clinic. The company was founded by Ian Huen on September 13, 2010 and is headquartered in Hong Kong.
Latest APM News From Around the Web
Below are the latest news stories about APTORUM GROUP LTD that investors may wish to consider to help them evaluate APM as an investment opportunity.
Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U GroupNEW YORK & LONDON & PARIS, March 27, 2023--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Company"), today announced that it entered into a non-binding Letter of Intent and Term Sheet ("Term Sheet") for the acquisition ("Transaction") of 100% of URF Holding Group Limited and its underlying businesses (collectively "U Group") by the further issuance of the Company’s class A ordinary shares as consideration. U Group’s business strategy, based on the |
Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)RedChip Companies will air new interviews with Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) and ASP Isotopes Inc. (Nasdaq:ASPI) on The RedChip Money Report® on Bloomberg TV, this Saturday, March 18, at 7 p.m. Eastern Time (ET). |
Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus AureusNEW YORK & LONDON & PARIS, March 03, 2023--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, announces the completion of the Pre-IND discussions with the US Food and Drug Administration ("US FDA"). ALS-4 is a first-in-class small molecule anti-virulence drug targeting infections caused by Staphylococcus aureus, including but not limited to Methicillin Resistant Staphylococcus Aureus ("MRSA"). |
Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting NeuroblastomaNEW YORK & LONDON & PARIS, March 03, 2023--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, announces the completion of an end of Phase 1 (EOP1) meeting with the US Food and Drug Administration ("US FDA"). SACT-1 is a repurposed small molecule drug formulated in oral suspension targeting neuroblastoma in pediatric patients and has also received orphan drug designation previously from the US FDA. |
Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in ChinaNEW YORK & LONDON & PARIS, March 02, 2023--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group"), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics to tackling unmet medical needs, announces the exciting commercial launch of NativusWell®, a new dietary supplement supporting women’s health throughout the Menopausal cycles targeting the China market. NativusWell® has commenced collaboration with one of the largest e-co |
APM Price Returns
| 1-mo | -9.09% |
| 3-mo | -45.83% |
| 6-mo | -74.09% |
| 1-year | -80.52% |
| 3-year | -90.10% |
| 5-year | N/A |
| YTD | -45.83% |
| 2022 | -63.33% |
| 2021 | -39.27% |
| 2020 | -84.42% |
| 2019 | 4.41% |
| 2018 | N/A |
Loading social stream, please wait...